Plasma levels of BDNF and EGF are reduced in acute stroke patients

The application of computerized quadrato motor training in enhancing balance and executive performance in stroke patients

This study investigated the effects of Computerized Quadrato Motor Training (CQMT) on balance and executive function in both single- and dual-task conditions for stroke patients. Patients (n = 60) were randomized to three groups: conventional training (CT), exercise training (ET), and interactive motor-cognitive training (IT). All participants underwent CT. Besides, the ET group undertook step training, and the IT group underwent CQMT for four weeks. The assessments comprised balance function, executive function, lower limb strength, as well as self-efficacy of balance control. Balance function was assessed via the Pro-Kin system and standardized scales (Berg Balance Scale [BBS], Tinetti Assessment [POMA]). Executive function was assessed by the Trail Making Test (TMT-A / B) and Stroop test. Dual-task cost (DTC) derived from Timed Up-and-Go Test with/without cognitive loading (TUGT / TUGTcog). Balance self-efficacy was assessed by the Activities-specific Balance Confidence (ABC) Scale, with lower limb strength assessed by Five-Times Sit-to-Stand (FTSTS). After the intervention, the ET significantly showed improvement in the elliptical trajectory area, BBS, and gait performance compared to CT(P < 0.05). The IT group demonstrated significantly greater improvements in balance parameters (swing speed, elliptical trajectory area, trajectory lengths; P < 0.05) and functional outcomes (BBS, POMA, FTSTS, Dual-Task performance, TMT, Stroop, ABC; P < 0.01) compared to both CT and ET. The IT group showed significant positive correlations between TMT improvements and enhanced Dual-ask performance. Our findings demonstrate that CQMT, as an integrative motor-cognitive intervention, significantly improves balance and executive function in stroke patients, thereby filling a critical gap in the clinical application of QMT in stroke rehabilitation research. These findings validate the 'guided plasticity facilitation' theory, highlighting CQMT as a cost-effective and broadly applicable clinical training.Trial registration: The clinical trial was registered on 08/10/2023, with the registration number ChiCTR2300076424.

The link between BDNF and platelets in neurological disorders

Platelets are considered one of the most important reservoirs not only of growth factors, but also of neurotrophic factors that could contribute to the repair of vascular lesions and the prevention of neurological deterioration. Among these factors, Brain-Derived Neurotrophic Factor (BDNF) - a protein belonging to the neurotrophin family - is widely expressed both in the hippocampus and in platelets. Platelets constitute an important reservoir of BDNF; however, little is known about the factors modulating its release into the circulation and whether anti-platelet drugs affect this secretion. In this review, we have discussed the link between BDNF and platelets and their role in neurological disorders.

Serum Irisin Levels are Inversely Correlated with Acute Ischaemic Stroke Incidence: Implications for Early Diagnosis in Southern China

Objective

This study aimed to examine the correlation and prognostic value of serum irisin levels in acute ischaemic stroke (AIS) and the subsequent development of hemiplegia.

Methods

This study recruited participants from the Department of Neurology and Rehabilitation Medicine at Shunde Hospital, Southern Medical University. The Fugl-Meyer Assessment was used to assess functional impairment. Serum irisin levels were measured using the enzyme-linked immunosorbent assay method. Multivariate logistic regression was employed to explore the factors related to serum irisin levels and AIS.

Results

Serum irisin levels in the AIS group were significantly lower than those in the control group. However, no significant association was observed between serum irisin and stroke severity within the AIS cohort. Multivariate logistic regression analysis revealed an inverse correlation between serum irisin levels and AIS risk, indicating that it serves as a protective factor against AIS. The increase in serum irisin levels (adjusted odds ratio (OR) 0.938, 95% confidence interval [CI]: 0.899-0.977 per 100 pg/mL increment) was associated with a decreased risk of AIS. Analysis of the receiver operating characteristic curve confirmed the diagnostic value of serum irisin for AIS, with the area under the curve being 0.591 (95% CI: 0.522-0.659, p = 0.012).

Conclusion

Serum irisin levels were significantly lower in AIS and were identified as a protective factor, suggesting that serum irisin may have diagnostic value for AIS.

Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial

Objective

This study tested the hypothesis that a neuroprotective combined therapy based on epidermal growth factor (EGF) and growth hormone-releasing hexapeptide (GHRP6) could be safe for acute ischemic stroke patients, admitting up to 30% of serious adverse events (SAE) with proven causality.

Methods

A multi-centric, randomized, open-label, controlled, phase I-II clinical trial with parallel groups was conducted (July 2017 to January 2018). Patients aged 18-80 years with a computed tomography-confirmed ischemic stroke and less than 12 h from the onset of symptoms were randomly assigned to the study groups I (75 μg rEGF + 3.5 mg GHRP6 i.v., n=10), II (75 μg rEGF + 5 mg GHRP6 i.v., n=10), or III (standard care control, n=16). Combined therapy was given BID for 7 days. The primary endpoint was safety over 6 months. Secondary endpoints included neurological (NIHSS) and functional [Barthel index and modified Rankin scale (mRS)] outcomes.

Results

The study population had a mean age of 66 ± 11 years, with 21 men (58.3%), a baseline median NIHSS score of 9 (95% CI: 8-11), and a mean time to treatment of 7.3 ± 2.8 h. Analyses were conducted on an intention-to-treat basis. SAEs were reported in 9 of 16 (56.2%) patients in the control group, 3 of 10 (30%) patients in Group I (odds ratio (OR): 0.33; 95% CI: 0.06-1.78), and 2 of 10 (20%) patients in Group II (OR: 0.19; 95% CI: 0.03-1.22); only two events in one patient in Group I were attributed to the intervention treatment. Compliance with the study hypothesis was greater than 0.90 in each group. Patients treated with EGF + GHRP6 had a favorable neurological and functional evolution at both 90 and 180 days, as evidenced by the inferential analysis of NIHSS, Barthel, and mRS and by their moderate to strong effect size. At 6 months, proportion analysis evidenced a higher survival rate for patients treated with the combined therapy. Ancillary analysis including merged treated groups and utility-weighted mRS also showed a benefit of this combined therapy.

Conclusion

EGF + GHRP6 therapy was safe. The functional benefits of treatment in this study supported a Phase III study.

Clinical Trial Registration

RPCEC00000214 of the Cuban Public Registry of Clinical Trials, Unique identifier: IG/CIGB-845I/IC/1601.

Batokine in Central Nervous System Diseases

Brown adipose tissue (BAT) is a special type of fat tissue in mammals and is also a key endocrine organ in the human body. Batokine, the endocrine effector of BAT, plays a neuroprotective role and improves the prognosis by exerting anti-apoptotic and anti-inflammatory effects, as well as by improving vascular endothelial function and other mechanisms in nerve injury diseases. The present article briefly reviewed several types of batokines related to central nervous system (CNS) diseases. Following this, the potential therapeutic value and future research direction of batokines for CNS diseases were chiefly discussed from the aspects of protective mechanism and signaling pathway.

Brain-Heart Axis: Brain-Derived Neurotrophic Factor and Cardiovascular Disease-A Review of Systematic Reviews

BACKGROUND

The brain-heart axis is an intra- and bidirectional complex that links central nervous system dysfunction and cardiac dysfunction. In recent decades, brain-derived neurotrophic factor (BDNF) has emerged as a strategic molecule involved in both brain and cardiovascular disease (CVD). This systematic review of systematic reviews aimed to (1) identify and summarize the evidence for the BDNF genotype and BDNF concentration in CVD risk assessment, (2) evaluate the evidence for the use of BDNF as a biomarker of CVD recovery, and (3) evaluate rehabilitation approaches that can restore BDNF concentration.

METHODS

A comprehensive search strategy was developed using PRISMA. The risk of bias was assessed via ROBIS.

RESULTS

Seven studies were identified, most of which aimed to evaluate the role of BDNF in stroke patients. Only two systematic reviews examined the association of BDNF concentration and polymorphism in CVDs other than stroke.

CONCLUSIONS

The overall evidence showed that BDNF plays a fundamental role in assessing the risk of CVD occurrence, because lower BDNF concentrations and rs6265 polymorphism are often associated with CVD. Nevertheless, much work remains to be carried out in current research to investigate how BDNF is modulated in different cardiovascular diseases and in different populations.

Remote Ischemic Conditioning for Motor Recovery after Acute Ischemic Stroke

BACKGROUND

Remote ischemic conditioning (RIC) has shown an impressive neuroprotective effect on acute ischemic stroke (AIS) in animal experiments. But whether chronic RIC improves long-term functional outcomes remains unclear.

MATERIALS AND METHODS

We performed a non-randomized controlled trial. Eligible patients (aged 18 -80 y) with hemiplegia caused by AIS were allocated to the RIC group and the control group. All participants received normal protocol rehabilitation therapy. Patients in the RIC group underwent RIC twice daily for 90 days. The outcome included the 90-day Fugl-Meyer Assessment (FMA) scores and modified Rankin's scale (mRS) scores, as well as changes in angiogenesis-related factors in serum from baseline to 90 days.

RESULTS

Twenty-seven patients were included in the analysis (13 in the RIC group and 14 in the control group). There was no significant difference in 90-day total FMA scores between the two groups. Lower limb FMA scores at day 90 were significantly higher in the RIC group (32.8±8.7 vs. 24.8±5.4, adjusted P =0.042). The proportion of favorable outcome (mRS<2) was higher in the RIC group than that in the control group, but no significant difference was detected (8 [61.5%] vs. 7 [50%], P =0.705). A significant increase has been found in the level of epidermal growth factor (EGF) in serum (9.4 [1.1 to 25.7] vs. -8.7 [-15.1 to 4.7], P =0.036) after chronic RIC procedure.

CONCLUSION

This study investigated the role that RIC plays in AIS recovery, especially in motor function. RIC may have beneficial effects on lower limbs recovery by enhancing the EGF level. The effect of RIC on motor recovery should be further validated in future studies.

Brain-Derived Neurotrophic Factor (BDNF) and Translocator Protein (TSPO) as Diagnostic Biomarkers for Acute Ischemic Stroke

Brain-derived neurotrophic factor (BDNF) interacts with tropomyosin-related kinase B (TrkB) to promote neuronal growth, survival, differentiation, neurotransmitter release, and synaptic plasticity. The translocator protein (TSPO) is known to be found in arterial plaques, which are a symptom of atherosclerosis and a contributory cause of ischemic stroke. This study aims to determine the diagnostic accuracy of plasma BDNF and TSPO levels in discriminating new-onset acute ischemic stroke (AIS) patients from individuals without acute ischemic stroke. A total of 90 AIS patients (61% male, with a mean age of 67.7 ± 12.88) were recruited consecutively in a stroke unit, and each patient was paired with two age- and gender-matched controls. The sensitivity, specificity, and area of the curve between high plasma BDNF and TSPO and having AIS was determined using receiver operating characteristic curves. Furthermore, compared to the controls, AIS patients exhibited significantly higher levels of BDNF and TSPO, blood pressure, HbA1c, and white blood cells, as well as higher creatinine levels. The plasma levels of BDNF and TSPO can significantly discriminate AIS patients from healthy individuals (AUC 0.76 and 0.89, respectively). However, combining the two biomarkers provided little improvement in AUC (0.90). It may be possible to use elevated levels of TSPO as a diagnostic biomarker in patients with acute ischemic stroke upon admission.

Serum Level of Brain-Derived Neurotrophic Factor and Thrombotic Type Are Predictive of Cognitive Impairment in the Acute Period of Ischemic Strokes Patients

40–70% of patients after a stroke, including a mild one, may experience cognitive impairment. Brain-derived neurotrophic factor (BDNF) plays a significant role in the pathogenesis and rehabilitation of ischemic stroke and also affects the patients’ recovery prognosis. An association between cognitive impairment in the poststroke period and lower peripheral BDNF levels is known, but the prognostic significance of serum BDNF levels and clinical characteristics for the risk of developing cognitive impairment in the acute period remains uncertain. We conducted a prospective cohort study of patients in the acute phase of ischemic stroke. Clinical examination, assessment of neurological status, neuropsychological testing, and laboratory analyzes were performed on patients at 1 and 14 days after ischemic stroke. The state of cognitive functions was assessed by the Mini-Mental State Examination scale. Quantification of BDNF in blood serum was performed by solid-phaseenzyme-linked immunosorbent assay (ELISA). We found that within 14 days after an acute ischemic stroke, we found a decrease in the clinical severity of patients compared to 1 day of the onset of the disease before the start of treatment and a significant decrease in the level of BDNF in the blood serum of patients with ischemic stroke both on the first and on the 14th day. However, during the 2 weeks of the acute period, no significant changes were detected, despite the general improvement of the clinical condition. In our study, cognitive impairment was found in almost half of the patients on the first day of ischemic stroke, and there was no significant reduction in this prevalence over 2 weeks. We found that a low level of BDNF and a thrombotic subtype of ischemic stroke can be risk factors for cognitive impairment in the acute period, which can be useful in planning treatment and rehabilitation measures.

Multi-assessment of critical steno-occlusive middle cerebral arteries: transcranial Doppler combined with magnetic resonance angiography

Background

Accurate assessment of a stenotic or occluded middle cerebral artery (MCA) is essential before making optimal therapeutic decisions. However, complete occlusion is not always easy to determine for both magnetic resonance angiography (MRA) and neurologists. We aimed to study noninvasive technology using transcranial Doppler (TCD) combined with MRA to assess severe stenosis and occlusion of the MCA.

Methods

We studied consecutive patients with severe steno-occlusive MCA by digital subtraction angiography from Oct. 2011 to Mar. 2020 in our stroke center. Hemodynamic measurements of TCD, including peak velocity (PSV), mean flow velocity (MFV) and pulse index (PI), were recorded specifically at the steno-occlusive site by MRA.

Results

A total of 152 MCAs of 148 patients were enrolled (60.0 ± 11.5 y, 107 male), including 82 severe stenotic MCAs and 70 occluded MCAs (Group S & Group O) by DSA. There were 86/152 (57%) MCAs showing discontinuity in MRA, which was significantly distributed more in Group O than in Group S (84% vs. 33%, P < 0.001). The PSV and MFV in Group S were greater (264 ± 78 cm/s vs. 33 ± 34 cm/s and 182 ± 61 cm/s vs. 21 ± 23 cm/s, respectively, P < 0.001), while the PI in Group O was greater (0.98 ± 0.49 vs. 0.72 ± 0.17, P < 0.001). PSV was positively correlated with severe MCA stenosis (β = 0.036, P < 0.001, OR = 0.965, 95% confidence interval (CI): 0.952–0.978). In severe steno-occlusive MCA, using PSV and MFV to detect MCA severe stenosis yielded areas under the curve of 0.983 (CI: 0.964–1.0) and 0.982 (CI: 0.962–1.0), respectively. The cutoff points of PSV ≥ 77 cm/s and MFV ≥ 51 cm/s both yielded an optimized sensitivity of 96.3% and specificity of 98.6%.

Conclusion

The critical velocity at the steno-occlusive site is reliable for distinguishing between severe MCA stenosis and occlusion.